News

Stroll secures £10.3m of funding

March 13, 2025

Portfolio company, Strolll, who develop Digital Therapeutics software for Augmented Reality glasses that empower movement therapy for people with neurological disorders, such as Parkinsons and MS; has secured £10.3m of funding.

Sky News reports that Strolll, which was founded five years ago, has secured the new capital in a round led by IW Capital.

Recently the Company begun a three-year, project grant-funded by the National Institute for Health and Care Research with the University of Leeds, University of York and four leading NHS trusts to conduct a randomised controlled trial of Strolll as a therapeutic treatment for patients with Parkinson’s disease.

They have also entered the US market supported by shareholder, Cleveland Clinic.

Martlet first invested in Strolll in their seed round in 2023 and subsequently played an active role on the Board.

The Company has said that it would use its new investment to accelerate sales and marketing activities, extend its product range, and to target additional neuro-related disorders.